Abstract
Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therapy has a narrow therapeutic window for optimal balance of risk and benefit, which requires regular assessment of the international normalized ratio (INR) to monitor coagulation. A quest for safer, more effective therapies that do not need monitoring has led to the development of dabigatran, rivaroxaban, and apixaban. In this article, we review these newer antithrombotic agents and discuss role of these drugs in clinical practice.
Keywords: Atrial fibrillation, Antithrombotic, Bleeding, Thromboembolism, Stroke, Clotting factors, embolism, antagonists, intracranial hemorrhage
Cardiovascular & Hematological Disorders-Drug Targets
Title:Antithrombotic Options for Atrial Fibrillation in 2012
Volume: 12 Issue: 1
Author(s): Jennifer Rude, Karla Quevedo, Lissette Rodriguez de Armas and Debabrata Mukherjee
Affiliation:
Keywords: Atrial fibrillation, Antithrombotic, Bleeding, Thromboembolism, Stroke, Clotting factors, embolism, antagonists, intracranial hemorrhage
Abstract: Atrial fibrillation (AF) is a common arrhythmia in clinical practice. An important component of the management of patients with AF involves prevention of thromboembolism and stroke. Coumarins, such as warfarin had been the only available oral antithrombotic agent for prevention of thromboembolism for many decades. Following intestinal absorption, coumarins inhibit multiple steps of the clotting cascade that leads to inhibition of coagulation factors II, VII, IX and X. In addition to delayed and variable inhibition of coagulation, coumarin therapy has a narrow therapeutic window for optimal balance of risk and benefit, which requires regular assessment of the international normalized ratio (INR) to monitor coagulation. A quest for safer, more effective therapies that do not need monitoring has led to the development of dabigatran, rivaroxaban, and apixaban. In this article, we review these newer antithrombotic agents and discuss role of these drugs in clinical practice.
Export Options
About this article
Cite this article as:
Rude Jennifer, Quevedo Karla, Rodriguez de Armas Lissette and Mukherjee Debabrata, Antithrombotic Options for Atrial Fibrillation in 2012, Cardiovascular & Hematological Disorders-Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/187152912801823110
DOI https://dx.doi.org/10.2174/187152912801823110 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Recent Patents on Regenerative Medicine Discovery of New Cardiovascular Hormones for the Treatment of Congestive Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets New Technologies in Male Contraception
Current Women`s Health Reviews Angiotensin II Blockade and Renal Protection
Current Pharmaceutical Design Clinical Applications of Creatine Supplementation on Paediatrics
Current Pharmaceutical Biotechnology Effects of Anticancer Drugs in Reproductive Parameters of Juvenile Male Animals and Role of Protective Agents
Anti-Cancer Agents in Medicinal Chemistry BPC 157 and Blood Vessels
Current Pharmaceutical Design Salutary Properties of YC-1 in the Cardiovascular and Hematological Systems
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiovascular Adverse Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Preparation and Evaluation of Novel Expandable Drug Delivery System with Captopril
Current Drug Therapy Enzymatic Properties and Physiological Roles of Cytosolic 5’-Nucleotidase II.
Current Medicinal Chemistry Cytotoxic and Radio-sensitizing Effects of Polyphenolic Acetates in a Human Glioma Cell Line (BMG-1)
Current Pharmaceutical Design Assessment of Cardiac Sympathetic Innervation in Heart Failure and Lethal Arrhythmias: Therapeutic and Prognostic Implications
Current Cardiology Reviews Microalbuminuria In Primary Hypertension
Current Hypertension Reviews Pitavastatin Improves Endothelial Function and Glucose Metabolism in Ovariectomized Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Dietary Fish Oil Concentrates Associated Health Benefits: A Recent Development of Cardiovascular Risk Reduction
Current Pharmaceutical Design Nitric Oxide: A Key Mediator of Biofilm Dispersal with Applications in Infectious Diseases
Current Pharmaceutical Design Antagonism by Bioactive Polyphenols Against Inflammation: A Systematic View
Inflammation & Allergy - Drug Targets (Discontinued) Pathophysiology of Airway Colonization in Critically ill COPD Patient
Current Drug Targets Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design